- Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
- TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
- TransCode Therapeutics Open Letter to Shareholders
- TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
- TransCode Therapeutics Reports 2023 Results; Provides Business Update
- TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
- TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
- TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
- TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
- Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
More ▼
Key statistics
On Wednesday, Transcode Therapeutics Inc (RNAZ:NAQ) closed at 0.8681, 106.69% above the 52 week low of 0.42 set on Apr 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.93 |
---|---|
High | 0.9589 |
Low | 0.8501 |
Bid | -- |
Offer | -- |
Previous close | 0.94 |
Average volume | 175.04k |
---|---|
Shares outstanding | 6.62m |
Free float | 6.61m |
P/E (TTM) | -- |
Market cap | 5.75m USD |
EPS (TTM) | -206.36 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 17:59 BST.
More ▼